Einmal wöchentliche vs. zweimal wöchentliche Carfilzomib-Gabe plus Dexamethason bei Patienten mit rezidiviertem und refraktärem multiplen Myelom (RRMM): Ergebnisse der randomisierten Phase-3-Studie A.R.R.O.W.

23rd Congress of European Hematology Association (EHA) – Abstract: No. S849, Mateos, MV et al.: A.R.R.O.W.-Studie

Once-weekly vs. Twice-weekly Carfilzomib dosing plus Dexamethasone in patients with relapsed and refractory Multiple Myeloma (RRMM): Results oft he randomized Phase 3 study A.R.R.O.W.

 

Conclusion:

“Once-weekly Kd at 20/70 mg/m2 significantly improved PFS and ORR vs twice-weekly Kd at 20/27 mg/m2. The incidence of AEs was comparable between groups. No new safety risks were found in the once-weekly group. Overall, once-weekly Kd showed favorable benefit-risk profile with a convenient dosing regimen vs twice-weekly Kd.”

 

Quelle:
Mateos, MV et al., EHA 2018, Oral Presentation. Abstract S849.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214544/maria-victoria.mateos.once-weekly.vs.twice-weekly.carfilzomib.dosing.plus.html?f=menu=14*media=3*speaker=34215